
At Nostos Genomics, we partner with genetic testing labs to give more people with genetic diseases a clear and fast diagnosis. To achieve this, we developed a platform that leverages a unique combination of machine learning and synthetic biology.

At Nostos Genomics, we partner with genetic testing labs to give more people with genetic diseases a clear and fast diagnosis. To achieve this, we developed a platform that leverages a unique combination of machine learning and synthetic biology.
Headquarters: Berlin, Germany
Founded: 2018
Product: AION — AI-driven variant interpretation platform (clinical/exome)
Total funding: ≈ $5.65–5.72M (early-stage rounds; most recent Feb 3, 2022)
Team size: 23 employees (reported)
Rare-disease genomics; clinical variant interpretation and diagnostic decision support for genetic testing labs.
2018
Genomics / Digital Health / Diagnostics
Recorded as an early pre-seed round
Recorded convertible note round
Most recent seed round closed
“Investors include venture firms and accelerators such as Amino Collective, WENVEST Capital, Frontline Ventures, Entrepreneurs First, Faber, 42CAP, and others; also received public funding from the European Regional Development Fund (via Investitionsbank Berlin).”